Granules India Ltd. moves to reshape its capital structure

• Conversion price: Rs 585 per warrant, with each warrant convertible into one equity share. The 25% upfront payment was Rs 146.25 per warrant; the balance payable on conversion is Rs 438.75. ^[1]
• Relative to the SEBI ICDR floor price: The cited warrant-allotment note does not state the SEBI ICDR floor price, so the exact premium or discount cannot be confirmed. It would be calculated as: `(Rs 585 / SEBI ICDR floor price) - 1`.
• Potential dilution: Full conversion would create 24,982,906 new shares. ^[2] Using the filing summary’s stated fully diluted share count of 272,796,921 shares, the warrants would represent approximately 9.16% of post-conversion equity. Existing public shareholders would therefore face a 9.16% relative dilution in their ownership; their aggregate stake would fall from 62.61% to approximately 56.88%, assuming no other share-count changes.

The filing does not disclose a verifiable split of the issue proceeds between debt reduction and the ongoing capex cycle for FY26–FY27. Consequently, the post-issue impact on net debt-to-equity cannot be calculated from the disclosed information.

The latest reported baseline is:

• Net debt: Rs 457.89 Crores in Q1 FY27 ^[3]
• Total equity: Rs 5,085.00 Crores, latest reported balance ^[4]
• Net debt-to-equity: 0.09x in Q1 FY27 ^[5]

Mechanically, the ratio would fall through two channels if the proceeds are equity-funded:

• The portion used for debt repayment would directly reduce net debt.
• The portion used for capex would increase the asset base but would not immediately reduce net debt; its benefit would depend on project commissioning and subsequent cash generation.

The post-infusion ratio would therefore be:

`Post-issue net debt-to-equity = (Rs 457.89 Crores − debt repayment from proceeds) / (Rs 5,085.00 Crores + net equity proceeds)`

This is only a framework, not a computed outcome. The specific debt-reduction amount, capex allocation, issue size, and whether the capex is funded entirely from proceeds or partly through additional borrowing could not be confirmed.

The warrants did not immediately change Granules India’s paid-up promoter percentage on allotment; the change occurred when they were converted into equity shares. The promoter group’s post-conversion holding reached 37.39%, which is 0.63 pp below Q1 FY27 and 1.43 pp below Q3 FY26, despite the promoter group receiving almost the entire warrant issue.

Promoter shareholding bridge

The September promoter sale reduced the group’s holding from 38.02% to 31.08% before conversion ^[6]. Conversion of 24,982,906 promoter warrants then added shares equivalent to 9.16% of the diluted capital, taking the group to 37.39% ^[7]. Thus, the warrant conversion substantially restored promoter ownership after the sale, but it did not take the group back to its earlier 38.02–38.82% range.

The February 2026 preferential allotment comprised 25 million warrants at Rs 585 each, with 24,982,906 issued to the promoter group and 17,094 to a non-promoter investor. Each warrant was convertible into one equity share within 18 months; 25% of the issue price, or Rs 146.25 per warrant, was paid upfront and the balance 75% was payable on conversion ^[1]. The broader preferential package also included 5,128,205 equity shares to non-promoter investors ^[1].

Comparison with documented pharmaceutical-sector peer infusion

Analytical read: Granules’ 18-month tenor is conventional rather than differentiated, matching the documented Sigachi structure. The more important distinction is allocation: Granules directed approximately 99.93% of the warrants to promoters, whereas Sigachi’s promoter allocation was approximately 68.18% of the proposed warrants, derived from 7.5 crore out of 11 crore ^[8]. Granules also discloses the cash-flow timing more clearly through its 25%/75% payment split.

The nominal prices—Rs 585 for Granules versus Rs 26.40 for Sigachi—should not be interpreted as a relative premium or discount without the contemporaneous market prices and applicable pricing reference for each issue. The evidence supports a comparison of tenor, promoter concentration and payment timing, but not a valuation-quality comparison of the exercise prices.